{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02025413",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Pro00032772"
      },
      "Organization": {
        "OrgFullName": "Duke University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method",
      "OfficialTitle": "Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method",
      "Acronym": "CTC-EMT"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2018",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "November 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2015",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2015",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "December 19, 2013",
      "StudyFirstSubmitQCDate": "December 30, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 1, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "December 19, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 20, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Duke University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Prostate Cancer Foundation",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "United States Department of Defense",
            "CollaboratorClass": "FED"
          },
          {
            "CollaboratorName": "Janssen Diagnostics, LLC",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The primary objective of the preliminary lead-in study is to determine whether circulating tumor cells in patients with metastatic progressive castration-resistant prostate cancer or metastatic progressive breast cancer can be captured using a novel mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based).\n\nThe primary objective of each comparative cohort (second stage, prostate cancer) is to compare the non-detection rate of circulating tumor cells between the standard and novel methods."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Metastatic Progressive Castration-resistant Prostate Cancer",
          "Metastatic Progressive Breast Cancer"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Device Feasibility",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "46",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Metastatic progressive castration-resistant prostate cancer",
            "ArmGroupType": "Other",
            "ArmGroupDescription": "Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Device: Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)"
              ]
            }
          },
          {
            "ArmGroupLabel": "Metastatic progressive breast cancer",
            "ArmGroupType": "Other",
            "ArmGroupDescription": "Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Device: Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Device",
            "InterventionName": "Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Metastatic progressive breast cancer",
                "Metastatic progressive castration-resistant prostate cancer"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Feasibility as measured by successfully detecting at least one CTC in at least 2 out of 10 subjects, comparing the non-detection rate over time.",
            "PrimaryOutcomeTimeFrame": "The change in non-detection rate will be measured by comparing samples from Screening, Cycle 3, and Progression (up to 3 years)"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Comparison of the proportion of patients with no detectable CTCs between capture methods over time",
            "SecondaryOutcomeTimeFrame": "Change will be measured by comparing samples at Screening, Cycle 3, Progression (up to 3 years)"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in CTCs (using each method) over time during systemic therapy",
            "SecondaryOutcomeTimeFrame": "Screening, Cycle 3, Progression (up to 3 years)"
          },
          {
            "SecondaryOutcomeMeasure": "Change in correlation of CTC enumeration using each method with baseline clinical and pathologic disease characteristics (for example, clinical stage, site of metastatic disease, Gleason sum for CRPC, PSA for CRPC, previous therapies)",
            "SecondaryOutcomeTimeFrame": "Screening, Cycle 3, Progression (up to 3 years)"
          },
          {
            "SecondaryOutcomeMeasure": "Median number of CTCs detected by each method over time",
            "SecondaryOutcomeTimeFrame": "Changes will be measured from screening, cycle 3 and progression (up to 3 years)"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nProstate cancer patients will be eligible for inclusion in this study only if all of the following criteria apply:\n\nHistologically confirmed diagnosis of adenocarcinoma of the prostate. Small cell or neuroendocrine tumors of the prostate are also permitted.\nClinical or radiographic evidence of metastatic disease.\nCastrate levels of testosterone (<50 ng/dl)\n\nEvidence of disease progression on or following most recent therapy as evidenced clinically by the treating physician or by either of the following:\n\nTwo consecutive PSA levels greater than the PSA nadir achieved on ADT, separated by greater than one week\nRadiographic evidence of disease progression as defined by new bone scan lesions or growth of soft tissue/visceral metastases >1 cm in diameter (2 cm for lymph nodes).\nAge > 18 years.\nAbility to understand and the willingness to sign a written informed consent document.\n\nBreast cancer patients will be eligible for inclusion in this study only if all of the following inclusion criteria apply:\n\nHistologically confirmed diagnosis of invasive breast cancer.\nClinical or radiographic evidence of metastatic disease.\nEvidence of disease progression on the current or following the most recent therapy, determined either clinically by the treating physician or by radiographic evidence as defined by new bone scan lesions or soft tissue/visceral metastases >1 cm in diameter (2 cm for lymph nodes).\nAge > 18 years.\nAbility to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nA patient will not be eligible for inclusion in this study if any of the following criteria apply:\n\nHistory of intercurrent or past medical or psychiatric illness that would make participation in a blood drawing protocol difficult or not feasible at the discretion of the principal investigator or co-investigator(s).\nTreatment with an anthracycline or mitoxantrone within 1 week of CTC collection",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Andrew J Armstrong, MD",
            "OverallOfficialAffiliation": "Duke University",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Duke University Medical Center",
            "LocationCity": "Durham",
            "LocationState": "North Carolina",
            "LocationZip": "27710",
            "LocationCountry": "United States"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009360",
            "ConditionMeshTerm": "Neoplastic Cells, Circulating"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009362",
            "ConditionAncestorTerm": "Neoplasm Metastasis"
          },
          {
            "ConditionAncestorId": "D000009385",
            "ConditionAncestorTerm": "Neoplastic Processes"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M4372",
            "ConditionBrowseLeafName": "Breast Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13487",
            "ConditionBrowseLeafName": "Prostatic Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11457",
            "ConditionBrowseLeafName": "Neoplastic Cells, Circulating",
            "ConditionBrowseLeafAsFound": "Circulating Tumor Cells",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11459",
            "ConditionBrowseLeafName": "Neoplasm Metastasis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11482",
            "ConditionBrowseLeafName": "Neoplastic Processes",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}